Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomised controlled trial
- 1 November 1998
- journal article
- clinical trial
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 105 (11) , 1148-1154
- https://doi.org/10.1111/j.1471-0528.1998.tb09967.x
Abstract
Objectives To ascertain whether uterine shrinkage induced by a gonadotrophin releasing hormone agonist before hysterectomy for fibroids increases the possibility of a vaginal procedure.Design A multicentre, prospective, randomised, controlled study.Participants One hundred and twenty‐seven premenopausal women with a uterine volume of 12 to 16 gestational weeks.Interventions Twelve weeks of triptorelin depot treatment before hysterectomy or immediate surgery.Main outcome measures Number of vaginal and abdominal hysterectomies, operating time, blood loss, degree of difficulty of the procedure, perioperative serum haemoglobin and haematocrit levels, hospital stay, and patients' overall satisfaction with treatment.Results After randomisation, four women withdrew from the study, leaving 60 women in the triptorelin arm and 63 in the immediate surgery arm. At baseline evaluation a vaginal hysterectomy was indicated in seven women allocated to pre‐operative medical therapy (12%), and in 10 of those allocated to immediate surgery (16%). Clinical assessment after the 12–week GnRH agonist course showed that abdominal hysterectomy was no longer indicated in 25/53 women (47%) as a vaginal procedure appeared appropriate. Thus the overall rate of indication for a vaginal procedure in the pre‐operative medical treatment arm was 32/60 cases (53%), with a between‐group difference of 37% (95% CI, 26% to 51%; χ21= 19.18, P < 0.0001; OR 6.06; 95% CI, 2.60 to 14.10). Pre‐ and post‐operative serum haemoglobin and haematocrit levels were significantly higher in the GnRH agonist than in the immediate surgery arm. No appreciable difference was observed between the groups in the other intra‐ and post‐operative variables, including patients' satisfaction.Conclusions Pre‐operative GnRH agonist therapy increased the rate of vaginal hysterectomy in selected women with fibroids and uterine volume of 12 to 16 gestational weeks.Keywords
This publication has 26 references indexed in Scilit:
- Endometrial resection versus vaginal hysterectomy for menorrhagia: Long-term clinical and quality-of-life outcomesAmerican Journal of Obstetrics and Gynecology, 1997
- Hysterectomy for benign gynecologic disordersPostgraduate Medicine, 1996
- Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort studyBJOG: An International Journal of Obstetrics and Gynaecology, 1995
- Guidelines to determine the route of hysterectomyObstetrics & Gynecology, 1995
- Abdominal hysterectomy versus transvaginal morcellation for the removal of enlarged uteriAmerican Journal of Obstetrics and Gynecology, 1994
- Length of hospital stay after vaginal hysterectomyBJOG: An International Journal of Obstetrics and Gynaecology, 1994
- Early discharge following vaginal hysterectomyBJOG: An International Journal of Obstetrics and Gynaecology, 1993
- Complications of vaginal hysterectomy under “difficult” circumstancesArchiv für Gynäkologie, 1991
- Vaginal Hysterectomy: The Large UterusJournal of Gynecologic Surgery, 1989
- Complications of abdominal and vaginal hysterectomy among women of reproductive age in the United StatesAmerican Journal of Obstetrics and Gynecology, 1982